AAV-based gene therapies for the muscular dystrophies
Year: 2019
Type: review
Abstract: Muscular dystrophy (MD) is a group of progressive genetic diseases affecting the musculature that are characterized by inflammatory infiltrates, necrosis and connective tissue and fat replacement of the affected muscles. Unfortunately, treatments do not exist for the vast majority of MD patients. Adeno-associated viral vector (AAV)-based gene therapy is thus emerging as a potential treatment for many types of MD. Treatments strategies based on AAV are being adapted for replacement of mutant disease-causing genes, knockdown of dominant disease-causing genes using antisense oligonucleotides or inhibitory RNAs, delivery of gene editing tools such as clustered regularly interspaced short palindromic repeats/Cas9 and effecting alterations in pre-mRNA splicing and by manipulating expression levels of modifier genes. Translational and clinical trial work focused on these types of AAV treatments for Duchenne MD, various limb girdle MDs, myotonic dystrophy 1, facioscapulohumeral MD, dysferlinopathies and congenital MDs are discussed here, with a focus on recent studies, pre-clinical large animal work and many promising ongoing and upcoming AAV clinical trials.
Source: Human Molecular Genetics
DOI: 10.1093/hmg/ddz128
Authors: Julie M Crudele, Jeffrey S Chamberlain
Institution: University of Washington
Language: English
Subfield: Genetics
Domain: Life Sciences
Keywords: muscular dystrophy, adeno-associated virus vectors, gene therapy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, dysferlinopathy, congenital muscular dystrophy, antisense oligonucleotides, RNA interference, CRISPR/Cas9 genome editing, pre-mRNA splicing, genetic modifiers, large animal model, clinical trials
Open Access status: green
Funders: Muscular Dystrophy Association, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Intellectual and Developmental Disabilities Research Center, Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy, G9000099203, Dystrophin Replacement, Diabetes Research Center, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center - Seattle
OpenAlex ID: W2955318787
